Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of SGI-110 plus Carboplatin in Platinum-Resistant Recurrent Ovarian Cancer
2012-001576-12Phase 2Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Feb 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of guadecitabine and carboplatin in ovarian cancer (2 arms), sponsored by Astex Pharmaceuticals. Started Feb 2013; status: completed.
02
Drugs
guadecitabinecarboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2012-001576-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001576-12.